Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase – Should You Buy?

Pharming Group (NASDAQ:PHAR) saw unusually-high trading volume on Tuesday . Approximately 5,484 shares traded hands during mid-day trading, an increase of 7% from the previous session’s volume of 5,115 shares.The stock last traded at $8.83 and had previously closed at $8.78.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PHAR. Oppenheimer dropped their price target on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Trading Up 0.8 %

The company’s fifty day moving average is $9.23 and its two-hundred day moving average is $8.43. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The stock has a market cap of $601.45 million, a price-to-earnings ratio of -34.00 and a beta of -0.10.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.